CBS-0550

From Wikipedia, the free encyclopedia
Jump to: navigation, search
CBS-0550
CBS-0550 structure.png
Systematic (IUPAC) name
N-[5-tert-butyl-2-(cyclopropylmethyl)-1-methylpyrazol-3-ylidene]-2-fluoro-3-(trifluoromethyl)benzamide
Clinical data
Legal status
?
Identifiers
CAS number 887289-02-3
ATC code ?
PubChem CID 24763642
ChemSpider 23320245
Chemical data
Formula C20H23F4N3O 
Mol. mass 397.409 g/mol

CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB2 receptor agonist, with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects.[1]

See also[edit]

References[edit]

  1. ^ Ohta H, et al. Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. Bioorganic and Medicinal Chemistry. 2008 Feb 1;16(3):1111-24. PMID 18006322